Market Cap | 1.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -112.11k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -3.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -77.00% |
Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 83.55M | 52W Low Chg | 87.00% |
Insider Own | 45.04% | ROA | -281.32% | Shares Float | 45.92M | Beta | 0.79 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 9,161 | Target Price | - |
Oper. Margin | - | Earnings Date | Oct 30 | Volume | 100 | Change | 14.63% |
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. The company develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for research applications, as well as portable delivery system. It serves hospitals, health systems, and the medical community. The company was incorporated in 2011 and is based in Port Jefferson, New York.